This company is no longer active
INDEX Stock Overview
Engages in the research and development of pharmaceuticals for immunological diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
InDex Pharmaceuticals Holding AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.55 |
| 52 Week High | SEK 0.93 |
| 52 Week Low | SEK 0.20 |
| Beta | -0.21 |
| 11 Month Change | 35.15% |
| 3 Month Change | 88.28% |
| 1 Year Change | -4.55% |
| 33 Year Change | -63.84% |
| 5 Year Change | -93.87% |
| Change since IPO | -92.20% |
Recent News & Updates
Market Might Still Lack Some Conviction On InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Even After 35% Share Price Boost
Jun 13
Further Upside For InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Shares Could Introduce Price Risks After 26% Bounce
Apr 28Recent updates
Market Might Still Lack Some Conviction On InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Even After 35% Share Price Boost
Jun 13Further Upside For InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Shares Could Introduce Price Risks After 26% Bounce
Apr 28We're Keeping An Eye On InDex Pharmaceuticals Holding's (STO:INDEX) Cash Burn Rate
Jul 11We Think InDex Pharmaceuticals Holding (STO:INDEX) Can Afford To Drive Business Growth
Jan 21We Think InDex Pharmaceuticals Holding (STO:INDEX) Can Afford To Drive Business Growth
Aug 31Here's Why We're Watching InDex Pharmaceuticals Holding's (STO:INDEX) Cash Burn Situation
Mar 29InDex Pharmaceuticals Holding's (STO:INDEX) Shareholders Are Down 24% On Their Investment Over The Past Year.
Feb 04
How Much Are InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Insiders Spending On Buying Shares?
Dec 21Shareholder Returns
| INDEX | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | 1.1% | 0.9% | -0.8% |
| 1Y | -4.5% | 93.6% | 13.6% |
Return vs Industry: INDEX underperformed the Swedish Pharmaceuticals industry which returned 88.4% over the past year.
Return vs Market: INDEX underperformed the Swedish Market which returned 14.1% over the past year.
Price Volatility
| INDEX volatility | |
|---|---|
| INDEX Average Weekly Movement | 7.5% |
| Pharmaceuticals Industry Average Movement | 10.1% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in SE Market | 12.7% |
| 10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: INDEX's share price has been volatile over the past 3 months.
Volatility Over Time: INDEX's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 4 | Jenny Sundqvist | www.indexpharma.com |
InDex Pharmaceuticals Holding AB (publ) engages in the research and development of pharmaceuticals for immunological diseases. The company was founded in 2000 and is headquartered in Solna, Sweden.
InDex Pharmaceuticals Holding AB (publ) Fundamentals Summary
| INDEX fundamental statistics | |
|---|---|
| Market cap | SEK 286.59m |
| Earnings (TTM) | -SEK 56.48m |
| Revenue (TTM) | SEK 108.34m |
2.7x
P/S Ratio-5.1x
P/E RatioIs INDEX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INDEX income statement (TTM) | |
|---|---|
| Revenue | SEK 108.34m |
| Cost of Revenue | SEK 4.03m |
| Gross Profit | SEK 104.31m |
| Other Expenses | SEK 160.79m |
| Earnings | -SEK 56.48m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 20, 2024
| Earnings per share (EPS) | -0.11 |
| Gross Margin | 96.28% |
| Net Profit Margin | -52.13% |
| Debt/Equity Ratio | 0% |
How did INDEX perform over the long term?
See historical performance and comparison